Fisher & Paykel Healthcare Corporation Limited logo

FPH reactivates dividend reinvestment plan

Dividend28 November 2022FPHHealthcare

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)


Fisher & Paykel Healthcare reactivates dividend reinvestment plan


Auckland, New Zealand, 29 November 2022 - Fisher & Paykel Healthcare Corporation Limited

(NZX:FPH, ASX:FPH) announced today that it is reactivating its dividend reinvestment plan (DRP)

for eligible shareholders residing in New Zealand, Australia and the United Kingdom.


Under the reactivated DRP, eligible shareholders may elect to reinvest all or part of their cash

dividends in additional shares. A 3% discount will be applied when determining the price per share

of shares issued under the DRP and will be applied in respect of the 2023 interim dividend and

future dividends, until such time as the directors determine otherwise.


Shareholders that previously opted into the plan will remain enrolled unless they terminate their

participation online at https://investorcentre.linkgroup.nz/ or by completing a cancellation form

available upon request from the company’s registrar, Link Market Services.


Shareholders not previously enrolled who wish to participate in respect of the FY2023 interim

dividend will need to opt into the plan via Link Market Services’ website at

https://investorcentre.linkgroup.nz/ or return a physical participation form before 5pm on 12

December 2022. The plan offer document and participation form are available on the company’s

website at www.fphcare.com/drp.


The strike price is calculated as the volume-weighted average sale price for an ordinary share,

calculated on all price-setting trades of shares which took place through the NZX Main Board over a

period of five trading days immediately following the dividend record date of 9 December 2022. The

company will issue an announcement of the strike price, inclusive of the 3% discount, once

calculated.


Fisher & Paykel Healthcare first introduced a dividend reinvestment plan in 2009 before suspending

it in 2019.


For more information, please contact Link Market Services at operations@linkmarketservices.co.nz

or +64 9 375 5998.


About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and

systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep

apnea. The company’s products are sold in over 120 countries worldwide. For more information

about the company, visit our website www.fphcare.com.



Media & Investor Contacts:


Karen Knott

GM Corporate Communications

karen.knott@fphcare.co.nz

+64 21 713 911

Hayden Brown

Investor Relations Manager

hayden.brown@fphcare.co.nz

+64 27 807 8073



Authorised by Fisher & Paykel Healthcare Corporation Limited’s Board of Directors.

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.